Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Mogamulizumab in Combination with Phototherapy for the Treatment of Stage IA-IIA Mycosis Fungoides, The PLIGHT Trial

Trial Status: closed to accrual

This early phase I trial tests the safety, side effects and effectiveness of mogamulizumab (POTELIGEO) given in combination with phototherapy in treating patients with stage IA-IIA mycosis fungoides (MF). Early stage MF is usually treated with skin directed therapies such as phototherapy, topical steroids, etc. Phototherapy is effective and tolerable but MF tends to return and many patients require long-term maintenance therapy. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Mogamulizumab in combination with phototherapy may be safe, tolerable, and/or effective in treating patients with stage IA-IIA MF.